RAS-Targeted Drug Discovery Summit 2019

Following the exciting clinical progression from Amgen and Mirati Therapeutics, at a time when there is a translational opportunity to finally “drug” RAS proteins with clinically meaningful success, the 1st RAS- Targeted Drug Discovery Summit has been established to unite large pharma, biotech and academic KOLs who are striving to capitalize on the therapeutic potential of targeting RAS. With RAS mutations prevalent in approximately 30% of all cancers diagnosed, the clinical, patient outcome and commercial opportunity are tremendous. As such, the RAS- Targeted Drug Discovery Summit will be dedicated to helping oncology drug discovery and development professionals understand the cutting edge dynamics and function of RAS biology, identify and validate druggable target sites and improve the preclinical predictability of patient-derived and disease-specific RAS models. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the 1st RAS- Targeted Drug Discovery Summit – the only industry and translational focused conference dedicated to advancing pioneering RAS biology and drug discovery into successful clinical candidates.

URLs:
Tickets https://go.evvnt.com/440028-2?pid=5248
Brochure https://go.evvnt.com/440028-3?pid=5248

Prices:
Conference Only (Industry): USD 2899.0,
Conference Only + 1 Workshop (Industry): USD 3399.0,
Conference Only + 2 Workshop (Industry): USD 3799.0,
Workshop Only (Industry): USD 599.0,
Conference Only (Academic): USD 2029.0,
Conference Only + 1 Workshop (Academic): USD 2379.0,
Conference Only + 2 Workshop (Academic): USD 2659.0,
Workshop Only (Academic): USD 499.0

Speakers: Haby Henary, Medical Director, Oncology Global Development, Amgen, Laurent Debussche, Vice President, Global Head Molecular Oncology Research Therapeutic Area, Sanofi RandD, Matthew A. Marx, Vice President, Drug Discovery, Mirati Therapeutics, Dominic Esposito Director, Protein Expression Laboratory, NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Mariano Barbacid, AXA-CNIO Professor of Molecular Oncology and Head of the Experimental Oncology Group, Spanish National Cancer Research Center (CNIO), Yi Liu, Chief Scientific Officer, Wellspring Biosciences, Huaixiang Hao, Investigator III Novartis, Institutes for BioMedical Research, Ralph Minter, Senior Director, Fellow, Antibody Discovery and Protein Engineering (ADPE), AstraZeneca, Sarah Ross, Team Leader and Lead Bioscientist, AstraZeneca, Early Oncology TDE, Francis Burrows, Vice President, Translational Research, Kura Oncology, Jan Smith, Vice President, Biology, Revolution Medicines, Terry Rabbitts, Professor of Molecular Immunology Weatherall Institute of Molecular Medicine, University of Oxford, Kenneth Westover, Associate Professor UT Southwestern, Medical Center, Russell Lipford Director, Oncology Research, Amgen, Sean Buchanan, Research Fellow, Eli Lilly, Benjamin Bader, Senior Scientist, Small Molecule Innovation, Bayer AG, Chiara Ambrogio, Senior Scientist Dana-Farber, Cancer Institute, Magnus Jaderberg, Head of RandD, Targovax, Alemayehu Gorfe, Associate Professor McGovern Medical School, University of Texas Health Science Canter at Houston, Antti Poso, Professor of Drug Design, University of Eastern Finland and University of Tübingen, Aparajita Hoskote Chourasia, Senior Scientist and Team Leader, BioTheryX, Behnam Nabet, Research Fellow- Dana Farber, Cancer Institute, Shohei Koide, Professor of Biologics Design, New York University School of Medicine and Perlmutter Cancer Center, Tatu Pantsar, Marie Skłodowska-Curie Fellow, University of Tübingen

Sesh by The Boston Calendar | Advertise Terms | Privacy Policy | About